Peptic ulcers are injury of the mucosal area immersed in gastric acid and pepsin, wherein the area is covered normally with mucin secreted from mucus cells \[[@B1],[@B2]\]. So, erosions and ulcers are caused by various factors including gastric oversecretion and retention, weakening and depleting agents of mucin layer, blood flow disturbances, and mucosal injury and inflammation \[[@B1]-[@B4]\]. The ulcer-inducing agents include non-steroidal anti-inflammatory drugs (NSAIDs) that block production prostaglandins (PGs), leading to mucin depletion and blood flow disturbances \[[@B5]-[@B9]\], alcohols \[[@B7],[@B8],[@B10]\], stresses \[[@B4],[@B7],[@B8]\], gastric oversecretion and retention \[[@B7],[@B8]\], gastric hypermotility and acetic acid accumulation \[[@B8],[@B11]-[@B14]\] and bacterial (*Helicobacter pylori*) infection \[[@B1],[@B2],[@B15]-[@B17]\].

It is well known that *H. pylori*, closely associated with peptic ulcers, chronic active gastritis and gastric malignancies, is a key factor for recurrence and aggravation of ulcers as well as development to gastric malignancies \[[@B18]-[@B20]\]. It is believed that *H. pylori* aggravates ulcers by continuously stimulating gastric secretion \[[@B21],[@B22]\]. Thus, elimination of *H. pylori* is a key point for ulcer treatment in adults exhibiting a high incidence \[[@B1],[@B2],[@B15],[@B17],[@B23],[@B24]\]. For the therapy of *H. pylori*-mediated gastritis and ulcers, triple therapies (omeprazole+clerithromycin+amoxicillin or omeprazole+clerithromycin+metronidazole) composed of proton-pump inhibitors (pantoprazole, omeprazole, lansoprazole, etc) and antibiotics (clarithromycin, metronidazole, amoxicillin, etc) have been recommended \[[@B2]\]. However, antibiotics used for triple therapy are becoming ineffective due to a rapidly-increasing tolerance of the bacteria \[[@B25]\].

In the present study, *in vitro* anti-bacterial activity and *in vivo* bacteria-eliminating efficacy of IgY specific for *H. pylori* obtained by immunization to hens were investigated in comparison with a proton-pump inhibitor pantoprazole. It has been reported that proton-pump inhibitors such as pantoprazole inhibit gastric secretion \[[@B26],[@B27]\], protect parietal cells \[[@B28]-[@B30]\], and suppress growth of *H. pylori* \[[@B31]-[@B33]\].

Materials and Methods
=====================

Materials
---------

Ig-Guard Helico®, egg york containing anti-*H. pylori* IgY (9.5 mg/g), obtained from immunized hens, were from ADbiotech Co., Ltd. (Chuncheon, Korea). In brief, *H. pylori* (KCTC12083) was cultured in Brucella agar containing 5% fetal bovine serum (FBS) at a 10% CO~2~ incubator (37℃), further in Brucella broth, and inactivated in 0.3% formalin for 12 hours. The inactivated antigen was centrifuged at 9,000 rpm for 15 min (4), and the pellet was adjusted to optical density (OD) of 0.5 at 410 nm. After mixing the antigen with ISA 70 adjuvant (3:7), the vaccine sample (3 mL) was intramuscularly inoculated to 22-week-old Hy-Line brown hens 3 times at 3-week intervals followed by boosting vaccination 35 days after the final inoculation. IgY-containing egg york was stored at -70℃ until use.

*H. pylori* culture and identification
--------------------------------------

*H. pylori* (ATCC49503) was obtained from American Type Culture Collection (Manassas, VA, USA), and cultured on brain heart infusion (BHI) broth in an anaerobic chamber with 10% CO~2~, 5% O~2~ and 85% N~2~ at 37℃ with enough humidity.

*In vitro* anti-bacterial activity
----------------------------------

The inhibitory capacity of IgY against the growth of *H. pylori* was assessed using agar-dilution method \[[@B32]\]. In brief, serially diluted IgY was added to Mueller Hinton agar containing 10% FBS, and *H. pylori* was inoculated on the agar. After 3-day incubation at 37℃, the IgY concentration fully inhibiting the bacterial growth was determined to be minimal inhibitory concentration (MIC).

Animals and treatment
---------------------

Male C57BL/6 mice (body weights 20-24 g) were procured from Daehan Biolink (Eumseong, Korea), and housed in a room with constant environmental conditions (22±2℃; 40-70% relative humidity; 12-hour light-dark cycle; 150-300 lux brightness). Pellet feed and purified water were available *ad libitum*. All the animal experiments were conducted according to the Standard Operation Procedures (SOP), and approved by the Institutional Animal Care and Use Committee of Chungbuk National University, Korea. For biosafety the investigators were fully protected with sterilized clothes, masks and gloves on SOP.

*H. pylori* infection and treatment
-----------------------------------

After 24-hour fasting, the mice (n=10/group) were orally inoculated with *H. pylori* (1×10^8^ CFU/1 mL/mouse) 3 times at 2-day intervals \[[@B17],[@B24]\]. Fourteen days later, a part of the animals (2 mice/group) were sacrificed to confirm infection using CLO *Helicobacter*-detection kits (Asan Pharm Co., Ltd., Seoul, Korea). The mice were orally treated with IgY (50, 100, 200 or 500 mg/kg) or pantoprazole (30 mg/kg) twice a day for 18 days.

Biopsy and bacterial identification
-----------------------------------

One day after the final administration, the mice were sacrificed and their gastric mucosa was biopsied for the detection of *H. pylori*. The biopsy samples (3×3 cm) from gastric pylorus were minced and applied to CLO kits and incubated at 35℃ for 24 hours to examine urease activity. The reaction (color change) was determined as negative for bright yellow, false (partially) positive for thick yellow, or positive for thick (dark) red.

Additional biopsy samples were obtained with a culture swab and inoculated to a medium containing 20% glycerol for identification of *H. pylori* as follows:

Oxidase: A colony was collected with a platinum-loop, and moved to a filter paper. After dropping *p*-phenylenediamine dihydrochloride solution, blue change following indolphenol blue production was determined as positive reaction.

Catalase: The colony grown in selective medium was placed on a slide, and bubbling following dropping 3% H~2~O~2~ was determined as positive reaction.

Nitrate reduction: Cultured colony was inoculated to nitrate broth, and incubated at 35℃ for 48 hours. Reddish purple change by adding α-naphthylamine and sulfanilic acid was determined as positive reaction.

H~2~S formation: The central portion of a colony was collected with a platinum-loop, and spread on the slant Triple sugar iron (TSI) medium. Black change following incubation at 37℃ for 24 hours with the lead open was determined as positive reaction producing H~2~S.

Histopathological examination
-----------------------------

Stomach was removed and fixed in neutral formalin solution. Paraffin-embedded tissue slides were stained with hematoxylin-eoson, and examined under a light microscope for the inflammatory lesions.

Statistical analysis
--------------------

Data were expressed as the mean±SEM. Statistical analysis was performed using an analysis of variance (ANOVA) with the aid of SPSS for Windows v.10.0 (Chicago, Illinois, USA). A *P* value \<0.05 was considered statistically significant.

Results
=======

Anti-bacterial activity
-----------------------

*In vitro* anti-bacterial test, 16 mg/mL and higher concentrations of IgY completely inhibited the growth of *H. pylori* following 3-day incubation of the bacteria (1×10^8^ CFU/mL) with a serially diluted IgY ([Table 1](#T1){ref-type="table"}). Therefore, MIC of IgY was determined to be 16 mg/mL, which was much higher than MIC of pantoprazole (2.2 mg/mL).

CLO kit test
------------

Repeated intragastric inoculation (1×10^8^ CFU, 3 times) of *H. pylori* to C57BL/6 mice revealed positive reaction (red color) in CLO test 14 days after the final inoculation, indicative of the bacterial infection in the stomach.

The mice orally treated with 50, 100, 200 or 500 mg/kg IgY twice a day for 18 days displayed positive reaction in 75% (6/8), 50% (4/8), 12.5% (1/8) and 12.5% (1/8) mice, respectively, in comparison with 100% (8/8) positivity at control (vehicle) group ([Table 2](#T2){ref-type="table"}). Although there was one case each in 200 and 500 mg/kg IgY group, no bacteria was detected in bacterial identification study. By comparison, 25% (2/8) positive reaction was achieved following treatment with pantoprazole (30 mg/kg).

Culture of gastric mucosa
-------------------------

From the culture of gastric mucosal specimen to confirm the presence of *H. pylori*, bacteria grew in all the samples from mice (100%) treated with vehicle ([Table 3](#T3){ref-type="table"}). However, IgY treatment decreased the detection ratio in a dose-dependent manner, leading to 70, 50, 12.5, and 12.5% at 50, 100, 200 and 500 mg/kg, respectively. Notably, there was no bacterial growth from the specimens that displayed partially positive reaction in CLO test. By comparison, pantoprazole (30 mg/kg) also reduced the detection ratio of bacterial growth to 25%.

*H. pylori* identification
--------------------------

The colonies grown from the gastric specimen were identified whether they are *H. pylori*. In urease test, all the colonies were identified as *H. pylori*, as also confirmed in CLO test. However, all the samples from mice including normal and vehicle groups exhibited positive reactivity to oxidase and catalase, regardless of treatment with IgY or pantoprazole, which might be due to the enzymes from mucosal tissue or microorganisms other than infected *H. pylori*. On the contrary, nitrate reduction and H~2~S formation, negative markers of *H. pylori*, were negative in all the samples including normal, vehicle and treated groups, implying that there were no nitrate-reducing and H~2~S-producing microorganisms or tissue enzymes and other agents.

Histopathological findings
--------------------------

*H. pylori* infection led to degeneration and slough of gastric villi with severe submocosal infiltration of inflammatory cells ([Figures 1A and 1B](#F1){ref-type="fig"}). IgY inhibited the inflammatory lesions, recovering to normal features with high doses (100-500 mg/kg), although light detachment of villi was observed at a low dose (50 mg/kg). Pantoprazole (30 mg/kg) also markedly improved the villi lesions. However, the histopathological features were in parallel with the presence of *H. pylori* as confirmed in CLO test and identification study.

Discussion
==========

Repeated (3 times) intragastric inoculation of *H. pylori* (ATCC49503, 1×10^8^ CFU/mouse) to male C57BL/6 mice revealed strong positive reaction in CLO test in 14 days, confirming good settlement of the bacteria. Interestingly, some normal animals without exposure to *H. pylori* displayed a weak (false or partially positive) reactivity, which may be due to the cross-reaction of other urease-producing bacteria such as *Klebsiella* and *Proteus* \[[@B34]\].

However, in comparison with the weak reactivity to ureases from *Klebsiella* and *Proteus* that are cytosolic proteins, CLO test detecting extracellular urease from *Helicobacter* is very strong so that the efficacy of the test is believed to be high. Notably, oxidase and catalase, positive identification markers of *H. pylori*, was displayed positive in normal animals too. Such a phenomenon might be due to the enzymes from tissues and/or other microorganisms. In contrast, nitrate reduction H~2~S formation, negative identification markers of *H. pylori*, was also negative in normal mice, indicating that there were no nitrate-reducing and H~2~S-producing microorganisms or tissue enzymes in the stomach. Such results point out that oxidase, catalase, nitrate reduction and H~2~S formation, besides urease, are not suitable markers for detection of *H. pylori* from biopsy specimens or in tissues. To overcome such a limitation of identification methods, we additionally examined the histopathological findings for the evaluation of *H. pylori*-induced inflammation and mucosal injuries including degeneration and sloughing of villi.

*In vitro* culture study, IgY exerted a relatively weak anti-*H. pylori* activity, with 1 mg/mL of MIC. The activity of IgY in our study was similar to that of *H. pylori*-specific IgY-Hp that inhibited bacterial growth and urease activity by 40 and 24.6% at 1 mg/mL, and 88 and 84.5% at 10 mg/mL, respectively \[[@B35]\]. In another study, *H. pylori* urease-specific IgY-HpU also inhibited urease activity by 29.9 and 81.7% at 1 and 10 mg/mL, respectively \[[@B36]\], leading to similar efficacies to IgY in the present study. On the other hand, IgY-HpUc specific for UreC subunit of urease exerted higher inhibitory effects on the growth and urease activity of *H. pylori* \[[@B37]\].

Treatment with IgY for 18 days eliminated *H. pylori* from the stomach of mice in a dose-dependent manner, reaching 87.5% at 200 or 500 mg/kg. Such anti-bacterial and anti-inflammatory effects of IgY seem to be higher than the efficacy of IgY-Hp that exhibited 50-60% anti-inflammatory activity at 180 mg/kg in a gerbil model \[[@B35]\]. Furthermore, the efficacy of IgY was superior to the *H. pylori*-elimination ratio (70%) of IgY-Hp58 specific for 58-kDa *H. pylori* (Hp) antigen \[[@B38]\]. On the other hand, it was reported that urease-specific IgY significantly attenuated gastric inflammation of gerbils fed at a concentration of 25 mg/g diet \[[@B39]\]. In the present study, *H. pylori* infection caused extensive degeneration and detachment of villi, accompanying severe infiltration of inflammatory cells. However, such pathological changes were remarkably recovered following eradication of bacteria by treatment of IgY or pantoprazole. It is of interest to note that bacterial identification was impossible in the animals showed partially-positive reaction in CLO test, which might be due to the urease released from the bodies or debris of dead *H. pylori*.

In previous studies, *in vivo* *H. pylori*-eliminating capacity of IgY specific for urease or subunit of urease has been demonstrated \[[@B37],[@B40]-[@B42]\]. However, since the titer of such antibodies tended to rapidly decrease at low pH, researches has focused on their efficacy in the stomach \[[@B40],[@B43]\]. Indeed, urease-specific IgY did not completely elliminated *H. pylori* from human patients, even though it markedly reduced expiratory urea concentration by alleviating gastritis and inhibiting urease activity \[[@B43],[@B44]\]. Thus, human trial for our IgY is necessary to assess its clinical efficacy. Furthermore, since synergistic effects in anti-bacterial and anti-inflammatory activities between IgY and lansoprazole or famotidine were achieved \[[@B39],[@B44],[@B45]\], combinational therapy of IgY and traditional drugs is also recommended.

In the present study, it was found that IgY inhibit the growth of *H. pylori* with 16 mg/mL of MIC, and improve gastritis and villi injuries by eliminating the bacteria from the stomach of mice. The results indicate that IgY could be a good candidate overcoming tolerance of antibiotics for the treatment of *H. pylori*-mediated gastric ulcers.

This work was supported in part by ADbiotech Co. and Priority Research Centers Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2010-0029709).

![Representative microscopic findings of the gastric mucosa of mice infected with *H. pylori* followed by treatment with IgY (50-200 mg/kg) or pantoprazole (30 mg/kg). Note the degeneration and sloughing of villi (A) and submocosal inflammatory cell infiltration (B) in vehicle group, in comparison with light sloughing of villi at a low (50 mg/kg) dose of IgY (C) and near-normal features at high doses of IgY (D, 100 mg/kg; E, 200 mg/kg) or pantoprazole (F, 30 mg/kg).](lar-28-55-g001){#F1}
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Minimum inhibitory concentration (MIC) of egg york (IgY) and pantoprazole
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Reactivity in CLO test on the gastric mucosa of mice infected with *H. pylori* followed by treatment with egg york IgY or pantoprazole
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○, negative; ◐, partially positive; ●, positive.
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Identification of *H. pylori* through culture of gastric mucosa from mice infected with *H. pylori* followed by treatment with egg york (IgY) or pantoprazole
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-, negative; +, positive.
